About

NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines. NewBiologix is committed to improve the generation and production of viral vectors used in gene and cell therapies by combining innovative and proprietary bioinformatics platform with advanced R&D experimentation. Next-generation sequencing (NGS)-based genome characterization will be used to develop an innovative and proprietary bioinformatics platform that will help cell line engineering through a combination of exceptionally in-depth datasets, sophisticated genomic analyses, and advanced R&D experimentation. NewBiologix’ technologies will be applied to human (HEK-293) and mammalian (CHO) cell lines engineered to be readily adaptable to meet the viral vector demands and requirements over a full range of products. With a strong Series A financing and an experienced start-up team established, NewBiologix anticipates cell line prototypes will be ready for beta testing with key collaborators by 2024 with the goal of commercially available viral production cell line lines by 2025. About NewBiologix NewBiologix is a technology innovation company developing proprietary platforms for the improved production of viral vectors used in gene and cell therapies. The company offers best-in-class rAAV variant screening, proprietary engineered HEK293 cell line programs, and next-generation sequencing (NGS) services including PacBio, Illumina, Nanopore, and Bionano. Our suite of technologies aims to help biopharmaceutical companies develop transformative gene therapies faster, safer, and at scale. About NewBiologix NewBiologix is a technology innovation company developing proprietary platforms for the improved production of viral vectors used in gene and cell therapies. The company offers best-in-class rAAV variant screening, proprietary engineered HEK293 cell line programs, and next-generation sequencing (NGS) services including PacBio, Illumina, Nanopore, and Bionano. Our suite of technologies aims to help biopharmaceutical companies develop transformative gene therapies faster, safer, and at scale. NewBiologix SA is a biotechnology company developing Swiss-engineered solutions for gene and cell therapy production. Specializing in cell line engineering, the company offers advanced cell lines and a genomic analytical platform, including the Xcell Engineered HEK293 Cell Line, custom high-quality AAV production, and cellular and viral genomic characterization with integrated bioinformatics. Our expertise enables partners to develop and scale gene therapies faster, while ensuring they are safer and more reliable.